SEC Form 4 · accession 0000899243-16-026126
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott A Holmes
Officer — Chief Financial Officer
Period of report
Jul 29, 2016
Accepted (ET)
Aug 2, 2016 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 29, 2016 | S | 4,935 | $7.36 | D | 108,557 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of a total of 4,935 shares of common stock was made in order to satisfy Mr. Holmes' income tax withholding obligation upon the vesting of 15,001 shares of restricted stock on July 27, 2016. Mr. Holmes had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- F2Includes 83,749 shares of restricted stock.